7 active trials 1 recruiting 10 disease areas 3 changes in 30 days
| Phase 1 | 3 | |
| Phase 1/2 | 1 | |
| Phase 2 | 3 |
| NCT ID | Title | Condition | Status | Updated |
|---|---|---|---|---|
| Phase 2 | ||||
| NCT04044768 | Spearhead 1 Study in Subjects With Advanced Synovial Sarcoma or Myxoid/Round Cell… | Synovial Sarcoma | Active, Not Recruiting | 2026-08-26 |
| NCT05601752 | ADP-A2M4CD8 Monotherapy and in Combination With Nivolumab in HLA-A2+ Subjects With… | Ovarian Cancer | Active, Not Recruiting | 2026-08-12 |
| NCT03967223 | Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered T… | Neoplasms | Active, Not Recruiting | 2026-08-11 |
| Phase 1/2 | ||||
| NCT05642455 | SPEARHEAD-3 Pediatric Study | Synovial Sarcoma | Recruiting | 2026-08-11 |
| Phase 1 | ||||
| NCT04044859 | ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in… | Endometrial Cancer | Active, Not Recruiting | 2026-08-12 |
| NCT03391778 | Adoptive Cell Therapy Long-term Follow-up (LTFU) Study | Neoplasms | Enrolling by Invitation | 2026-08-11 |
| NCT03132922 | MAGE-A4ᶜ¹º³²T for Multi-Tumor | Urinary Bladder Cancer | Active, Not Recruiting | 2026-06-04 |
Ovarian Cancer (3) · Sarcoma (3) · Non-Small Cell Lung Cancer (NSCLC) (2) · Melanoma (2) · Head & Neck Cancer (2) · Esophageal Cancer (2) · Lung Cancer (1) · Gastric Cancer (1) · Bladder Cancer (1) · Endometrial Cancer (1)